Pfiz­er spin­out Spring­Works gets FDA pri­or­i­ty re­view for lead drug

A Pfiz­er spin­out is get­ting a quick date with reg­u­la­tors for its “pipeline-in-a-prod­uct.”

Spring­Works Ther­a­peu­tics an­nounced Mon­day morn­ing that the FDA grant­ed nirogace­s­tat, the biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER